Federal Register Notice: FDA has determined the regulatory review period for GlaxoSmithKline’s Votrient (pazopanib hydrochloride) is 2,568 days for extending a patent which claims the human drug product. Votrient is a kinase inhibitor indicated for treating patients with advanced renal cell carcinoma. To view this notice, click here.
